Back to results
US 11,857,608 B2Granted
Dosage forms of tissue kallikrein 1
AssigneeDiaMedica Inc.
InventorsRick Pauls, Todd Verdoorn
Life of this patent
Estimating the term…
Abstract
Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 μg/kg to about 10.0 μg/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
Claims24
A method of treating an ischemic condition in a subject in need thereof, comprising subcutaneously or intravenously administering to the subject a dosage form comprising
- a first tissue kallikrein (KLK1) polypeptide and a second KLK1 polypeptide which are formulated at a total KLK1 polypeptide dosage of 0.5 μg/kg to 5.0 μg/kg,
- wherein the first KLK1 polypeptide has three N-linked glycans attached at residues 78, 84, and 141 as defined by SEQ ID NO:
- 3 or 4, and the second KLK1 polypeptide has two N-linked glycans attached at residues 78 and 84 but not 141 as defined by SEQ ID NO:
- 3 or 4;
- and
- wherein the first KLK1 polypeptide and the second KLK1 polypeptides are present in the dosage form at a ratio of about 45:55 to about 55:45.
3 more elements
Dependencies are inferred from the claim text.